Back to blog

Choosing Blood Biomarkers for Geroscience Trials: The TAME Framework

The TAME Biomarkers Workgroup proposes a clear framework for picking blood biomarkers in geroscience trials. It separates analytic from clinical validity, focuses on reliability and variability, and favors feasible secondary endpoints over hype.

Choosing Blood Biomarkers for Geroscience Trials: The TAME Framework |…

Key idea

A 2019 report from the TAME (Targeting Aging with Metformin) Biomarkers Workgroup lays out a practical way to choose blood biomarkers for geroscience-guided clinical trials. The aim is to select measures that are analytically sound, biologically grounded, clinically relevant, and likely to change during a trial—without claiming they replace hard clinical outcomes.

In short, a biomarker is a measurable indicator of biology. A good geroscience biomarker should be accurate, reliable, linked to aging processes and age-related disease risk, and responsive within the study window.

Note: This article is educational and is not medical advice.

Why this matters

Geroscience seeks to delay multiple age-related diseases by acting on shared biological pathways. But major events (for example, cardiovascular disease, cancer, disability) unfold over years. Trustworthy biomarkers let researchers detect meaningful biological shifts in shorter trials. The TAME framework helps:

  • separate enticing but unstable signals from measures that stand up to practical scrutiny;
  • prioritize panels that can capture shifts in aging biology over the duration of a trial;
  • standardize sampling and lab work to reduce measurement error and batch effects (systematic differences between runs or labs).

What the authors proposed

The Workgroup provides criteria for selecting blood biomarkers as secondary endpoints (supportive measures alongside clinical outcomes). They separate evaluation into layers.

1) Analytic validity

How well does the test measure what it claims?

  • Accuracy and reproducibility: known limits of detection and assay variability.
  • Test–retest reliability: stability when the same person is measured repeatedly.
  • Pre-analytic factors: time of day, fasting, posture, processing delays, and storage temperature.
  • Batch effects: consistency across reagent lots, instruments, technicians, and laboratories.

2) Biological plausibility and aging relevance

  • Mechanistic rationale: a credible link to pathways implicated in aging.
  • Association with age and multimorbidity: whether the marker changes with age and relates to risk across multiple age-related conditions.

3) Clinical validity and responsiveness

  • Prognostic value: association with future clinical outcomes.
  • Sensitivity to change: directionally appropriate shifts after an intervention.
  • Time course: enough dynamics to be informative within the trial’s duration.

Important: Biomarkers are not the same as surrogate endpoints. A surrogate is a biomarker validated to predict clinical benefit; it requires much stronger evidence. The TAME framework treats biomarkers mainly as informative secondary endpoints.

4) Variability and person-level interpretation

  • Within-person variability: natural fluctuation without intervention.
  • Minimal meaningful change: what shift is biologically and statistically interpretable for individuals and groups.

5) Feasibility and standardization

  • Sample type and logistics: serum, plasma, or whole blood; sample volume; draw frequency; participant burden.
  • Cost and scalability: can the assay be deployed widely without loss of quality?
  • SOPs and biobanking: standard operating procedures and long-term storage for future analysis.

6) Multi-marker panels

No single marker captures the breadth of aging biology. Panels are encouraged if:

  • each component has independent analytic validity;
  • composite construction is transparent and guarded against overfitting (models that perform well only in the training data);
  • performance is robust across platforms and labs.

Application to TAME

In TAME, blood biomarkers were envisioned as secondary endpoints to complement clinical outcomes. Selection emphasized markers that:

  • reflect plausible pathways targeted by the intervention;
  • are available in standardized, validated assays;
  • show reasonable test–retest reliability and manageable within-person variability;
  • are likely to change over time spans consistent with the trial.

The Workgroup underscores strict protocols for collection and storage, centralized or harmonized testing, and upfront plans to monitor and mitigate batch effects.

What this means in real life

  • For researchers: apply multi-layer vetting—from analytic validity to clinical relevance—before elevating a marker to a secondary endpoint. Build logistics, quality control, and statistical plans for panels from day one.
  • For readers and participants: popular “biological age” scores and other flashy metrics should be judged by validity and reliability. Without surrogate validation, biomarkers do not substitute for real clinical outcomes.
  • For regulators and sponsors: clarify aims—mechanistic biomarkers can illuminate impact, while validated surrogates support efficacy decisions.

Evidence quality

This is a framework report from a workgroup, not a randomized trial or meta-analysis. It systematizes criteria and practical considerations for biomarker selection in geroscience trials, drawing on expert consensus and the TAME design experience. Strength: methodological clarity. Limitation: no new efficacy data for specific markers.

Limitations and uncertainties

  • Focus on blood biomarkers: findings may not fully generalize to tissue, imaging, or digital measures.
  • Evolving technologies: omics platforms and composite scores change rapidly; validity can be platform-dependent.
  • Concepts like “biological age” require longitudinal testing for prognostic value and clinical significance.

Practical takeaways

  • Vet three layers for each marker: analytic validity, biological rationale, and clinical relevance.
  • Control pre-analytical factors and batch effects: standardized SOPs, calibration, and blinded repeats.
  • Quantify test–retest reliability and within-person variability before launch.
  • Use panels with transparent methods and independent validation of components.
  • Treat biomarkers as informative secondary endpoints unless and until they are validated as surrogates.

The TAME message is clear: in geroscience, biomarkers are tools, not trophies. Their value depends on how reliably and meaningfully they reflect the impact of interventions on aging biology, complementing—not replacing—hard clinical outcomes.

Sources